Investors Asset Management Of Georgia Inc Madrigal Pharmaceuticals, Inc. Transaction History

Investors Asset Management Of Georgia Inc

$208 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Jul 29, 2024	SELL	$193.33 - $291.99 $28,999 - $43,798	-150 Reduced 17.14%	725 $203,000
Q1 2024 Apr 22, 2024	BUY	$171.37 - $283.23 $149,948 - $247,826	875 New	875 $233,000

Others Institutions Holding MDGL

# of Institutions

298

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

Janus Henderson Group PLC London, X0

2.48M
Shares

$834 Million
0.28% of portfolio
John Paulson Paulson & Co. Inc. | New York, Ny

2.04M
Shares

$688 Million
29.57% of portfolio
Avoro Capital Advisors LLC New York, NY

2.03M
Shares

$683 Million
6.48% of portfolio
Rtw Investments, LP New York, NY

1.99M
Shares

$671 Million
6.74% of portfolio
Baker Bros. Advisors LP New York, NY

1.97M
Shares

$665 Million
4.49% of portfolio

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.76B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Investors Asset Management Of Georgia Inc , based on Form 13F filings with the SEC.

News

Stay updated on Investors Asset Management Of Georgia Inc with notifications on news.

Account